BlackRock Inc. Takes $186.59 Million Position in Immunome, Inc. $IMNM

BlackRock Inc. purchased a new position in shares of Immunome, Inc. (NASDAQ:IMNM) in the second quarter, HoldingsChannel reports. The firm purchased 8,805,492 shares of the company’s stock, valued at approximately $186,588,000. BlackRock Inc. owned 0.08% of Immunome as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of IMNM. KBC Group NV acquired a new position in Immunome in the first quarter valued at about $60,000. Strs Ohio acquired a new stake in shares of Immunome during the fourth quarter valued at about $64,000. Assetmark Inc. increased its position in shares of Immunome by 46.6% during the first quarter. Assetmark Inc. now owns 4,535 shares of the company’s stock valued at $99,000 after acquiring an additional 1,442 shares during the last quarter. State of Wyoming purchased a new stake in shares of Immunome in the 2nd quarter valued at approximately $109,000. Finally, Aster Capital Management DIFC Ltd purchased a new stake in shares of Immunome in the 4th quarter valued at approximately $121,000. 44.58% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

IMNM has been the subject of a number of research analyst reports. Wedbush increased their price objective on shares of Immunome from $31.00 to $35.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 12th. Citigroup reissued a “buy” rating on shares of Immunome in a research report on Thursday, July 9th. Leerink Partners decreased their price target on Immunome from $37.00 to $33.00 and set an “outperform” rating on the stock in a research note on Friday, May 15th. Truist Financial raised their price target on Immunome from $37.00 to $38.00 and gave the stock a “buy” rating in a research report on Wednesday, August 12th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunome in a research note on Friday, July 17th. Twelve research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $34.64.

Insider Buying and Selling

In related news, Director Isaac Barchas sold 101,050 shares of the company’s stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of $21.12, for a total transaction of $2,134,176.00. Following the sale, the director directly owned 308,504 shares in the company, valued at approximately $6,515,604.48. This represents a 24.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kinney Horn sold 90,616 shares of the firm’s stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $25.09, for a total transaction of $2,273,555.44. Following the completion of the sale, the insider directly owned 50,366 shares in the company, valued at approximately $1,263,682.94. This trade represents a 64.27% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 682,310 shares of company stock valued at $15,675,566. Corporate insiders own 7.21% of the company’s stock.

Immunome Trading Up 0.4%

NASDAQ:IMNM opened at $28.87 on Friday. Immunome, Inc. has a 12-month low of $8.66 and a 12-month high of $30.06. The firm has a market cap of $3.28 billion, a PE ratio of -11.41 and a beta of 2.08. The stock has a fifty day moving average price of $24.02 and a 200 day moving average price of $22.41.

Immunome (NASDAQ:IMNM) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.14). Equities analysts forecast that Immunome, Inc. will post -2.38 EPS for the current year.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.